154 related articles for article (PubMed ID: 27448700)
1. Efficacy of high intensity atorvastatin versus moderate intensity atorvastatin for acute coronary syndrome patients with diabetes mellitus.
Liu Z; Xu Y; Hao H; Yin C; Xu J; Li J; Wang Y; Xu D
Int J Cardiol; 2016 Nov; 222():22-26. PubMed ID: 27448700
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of High-Intensity Atorvastatin for Asian Patients Undergoing Percutaneous Coronary Intervention.
Liu Z; Joerg H; Hao H; Xu J; Hu S; Li B; Sang C; Xia J; Chu Y; Xu D
Ann Pharmacother; 2016 Sep; 50(9):725-33. PubMed ID: 27307415
[TBL] [Abstract][Full Text] [Related]
3. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.
Berwanger O; Santucci EV; de Barros E Silva PGM; Jesuíno IA; Damiani LP; Barbosa LM; Santos RHN; Laranjeira LN; Egydio FM; Borges de Oliveira JA; Dall Orto FTC; Beraldo de Andrade P; Bienert IRC; Bosso CE; Mangione JA; Polanczyk CA; Sousa AGMR; Kalil RAK; Santos LM; Sposito AC; Rech RL; Sousa ACS; Baldissera F; Nascimento BR; Giraldez RRCV; Cavalcanti AB; Pereira SB; Mattos LA; Armaganijan LV; Guimarães HP; Sousa JEMR; Alexander JH; Granger CB; Lopes RD;
JAMA; 2018 Apr; 319(13):1331-1340. PubMed ID: 29525821
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome.
Liu Z; Hao H; Yin C; Chu Y; Li J; Xu D
Oncotarget; 2017 Jun; 8(25):41582-41589. PubMed ID: 28177908
[TBL] [Abstract][Full Text] [Related]
5. The functional effect of atorvastatin dose-dependent via inflammation factors on acute ST segment elevation myocardial infarction after emergency percutaneous coronary intervention.
Liu Q; Wang Y; Cheng X
J Cardiovasc Med (Hagerstown); 2019 Apr; 20(4):215-219. PubMed ID: 30222665
[TBL] [Abstract][Full Text] [Related]
6. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
[TBL] [Abstract][Full Text] [Related]
7. Intensive Statin Therapy in NSTE-ACS Patients Undergoing PCI: Clinical and Biochemical Effects.
Shehata M; Fayez G; Nassar A
Tex Heart Inst J; 2015 Dec; 42(6):528-36. PubMed ID: 26664304
[TBL] [Abstract][Full Text] [Related]
8. Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial.
Lopes RD; de Barros E Silva PGM; de Andrade Jesuíno I; Santucci EV; Barbosa LM; Damiani LP; Nakagawa Santos RH; Laranjeira LN; Dall Orto FTC; Beraldo de Andrade P; de Castro Bienert IR; Alexander JH; Granger CB; Berwanger O
JAMA Cardiol; 2018 Nov; 3(11):1113-1118. PubMed ID: 30264159
[TBL] [Abstract][Full Text] [Related]
9. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
[TBL] [Abstract][Full Text] [Related]
10. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
[TBL] [Abstract][Full Text] [Related]
11. Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.
Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
Arterioscler Thromb Vasc Biol; 2014 Nov; 34(11):2465-72. PubMed ID: 25212234
[TBL] [Abstract][Full Text] [Related]
12. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
[TBL] [Abstract][Full Text] [Related]
13. Long-term benefits of high-intensity atorvastatin therapy in Chinese acute coronary syndrome patients undergoing percutaneous coronary intervention: A retrospective study.
Liu H; Dong A; Wang H
Medicine (Baltimore); 2018 Oct; 97(42):e12687. PubMed ID: 30334951
[TBL] [Abstract][Full Text] [Related]
14. What Is the Appropriate Duration of High-Dose Atorvastatin Therapy Post-Acute Coronary Syndrome?
Goriacko P; Andersen M; Fazylov R; Plakogiannis R
J Pharm Pract; 2015 Dec; 28(6):555-60. PubMed ID: 25107416
[TBL] [Abstract][Full Text] [Related]
15. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Ojeifo O; Wiviott SD; Antman EM; Murphy SA; Udell JA; Bates ER; Mega JL; Sabatine MS; O'Donoghue ML
JACC Cardiovasc Interv; 2013 Dec; 6(12):1275-81. PubMed ID: 24239201
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
Kim JS; Kim J; Choi D; Lee CJ; Lee SH; Ko YG; Hong MK; Kim BK; Oh SJ; Jeon DW; Yang JY; Cho JR; Lee NH; Cho YH; Cho DK; Jang Y
JACC Cardiovasc Interv; 2010 Mar; 3(3):332-9. PubMed ID: 20298994
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of the atherogenic index of plasma in type 2 diabetes mellitus patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Ma X; Sun Y; Cheng Y; Shen H; Gao F; Qi J; Yang L; Wang Z; Shi D; Liu Y; Liu X; Zhou Y
Lipids Health Dis; 2020 Nov; 19(1):240. PubMed ID: 33198752
[TBL] [Abstract][Full Text] [Related]
18. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
Rosenson RS; Hislop C; Elliott M; Stasiv Y; Goulder M; Waters D
J Am Coll Cardiol; 2010 Sep; 56(14):1079-88. PubMed ID: 20863951
[TBL] [Abstract][Full Text] [Related]
19. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study).
Hiro T; Kimura T; Morimoto T; Miyauchi K; Nakagawa Y; Yamagishi M; Ozaki Y; Kimura K; Saito S; Yamaguchi T; Daida H; Matsuzaki M;
J Am Coll Cardiol; 2009 Jul; 54(4):293-302. PubMed ID: 19608026
[TBL] [Abstract][Full Text] [Related]
20. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
Ray KK; Nicholls SJ; Ginsberg HD; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Toth PP; Wong N; Cummings JL; Sweeney M; Schwartz GG
Am Heart J; 2019 Nov; 217():72-83. PubMed ID: 31520897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
